VEKLURY

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, South Africa, Spain, UK.

Active ingredients

The drug VEKLURY contains one active pharmaceutical ingredient (API):

1	Remdesivir UNII 3QKI37EEHE - REMDESIVIR
	Remdesivir is an adenosine nucleotide prodrug that is metabolized within host cells to form the pharmacologically active nucleoside triphosphate metabolite. Remdesivir triphosphate acts as an analog of adenosine triphosphate (ATP) and competes with the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RNA-dependent RNA polymerase, which results in delayed chain termination during replication of the viral RNA. As an additional mechanism, remdesivir triphosphate can also inhibit viral RNA synthesis following its incorporation into the template viral RNA as a result of read-through by the viral polymerase that may occur in the presence of higher nucleotide concentrations.
	Read more about Remdesivir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VEKLURY Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AB16		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Discover more medicines within J05AB16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	546821040001101
CA	Health Products and Food Branch	02502143
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	6608-MEE-0921
EE	Ravimiamet	1821822, 1822115
ES	Centro de información online de medicamentos de la AEMPS	1201459002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	542115
FR	Base de données publique des médicaments	69284439
GB	Medicines & Healthcare Products Regulatory Agency	387373, 387471
HK	Department of Health Drug Office	66766
IL	מִשְׂרַד הַבְּרִיאוּת	8891
IT	Agenzia del Farmaco	048854018, 048854020
JP	医薬品医療機器総合機構	6250407D1020
LT	Valstybinė vaistų kontrolės tarnyba	1090741, 1090742
PL	Rejestru Produktów Leczniczych	100437716, 100437722
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67196001, W67197001
US	FDA, National Drug Code	61958-2901, 61958-2902
ZA	Health Products Regulatory Authority	55/20.2.8/0458